Companies celebrate new stem cell center as an alliance and recruitment catalyst

The recent DKK 2.2bn (USD 330m) grant the Novo Nordisk Foundation has allocated to a center focusing on stem cell treatments has been welcomed with open arms by pharmaceutical companies, who are jostling to enter the field.

When Novo Nordisk announced that it was investing DKK 2.2bn (USD 330m) in an international stem cell center on Friday, this was music to the ears of many pharmaceutical companies.

The grant Novo Nordisk has allocated to reNEW research center is the largest of its kind, and companies based in Copenhagen are particularly excited about the investment in stem cell treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs